- Conditions
- HIV
- Interventions
- Autologous CD4+ T cells genetically modified with a retroviral vector expressing the MazF endoribonuclease gene (MazF-T), given via intravenous infusion.
- Genetic
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Chagas Disease
- Interventions
- Testing Donor Specimens with ESA Chagas
- Device
- Lead sponsor
- Abbott Diagnostics Division
- Industry
- Eligibility
- 17 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 2
- States / cities
- Rosemont, Illinois • Gaithersburg, Maryland
- Conditions
- Seasonal Influenza Preventative Vaccine Pharmacodynamics
- Interventions
- VXA-A1.1 H1 Tablet Vaccine (small), VXA-A1.1 H1 Tablet Vaccine (large)
- Biological
- Lead sponsor
- Vaxart
- Industry
- Eligibility
- 18 Years to 49 Years · Male only
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- X-linked Retinoschisis
- Interventions
- rAAV2tYF-CB-hRS1
- Biological
- Lead sponsor
- Beacon Therapeutics
- Industry
- Eligibility
- 6 Years and older · Male only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 9
- States / cities
- San Francisco, California • Miami, Florida • Baltimore, Maryland + 6 more
- Conditions
- Hemophilia B
- Interventions
- SPK-9001
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 9
- States / cities
- Sacramento, California • Jackson, Mississippi • Madison, Mississippi + 2 more
- Conditions
- Malaria
- Interventions
- Chloroquine Phosphate, Pyrimethamine, Sanaria PfSPZ Challenge
- Drug · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Breast Cancer
- Interventions
- Ad-sig-hMUC-1/ecdCD40L vaccine
- Biological
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Pregnancy, Malaria
- Interventions
- Not listed
- Lead sponsor
- Amivas Inc.
- Industry
- Eligibility
- 15 Years to 100 Years · Female only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 1
- States / cities
- Piscataway, New Jersey
- Conditions
- Hemophilia A
- Interventions
- BAX 888
- Drug
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 18 Years to 75 Years · Male only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Los Angeles, California • Sacramento, California + 5 more
- Conditions
- Leber Congenital Amaurosis
- Interventions
- voretigene neparvovec-rzyl
- Biological
- Lead sponsor
- Spark Therapeutics, Inc.
- Industry
- Eligibility
- 8 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Yellow Fever
- Interventions
- Not listed
- Lead sponsor
- Rockefeller University
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Zika Virus, Congenital Zika Syndrome, Congenital Infection, Child Development
- Interventions
- Neurodevelopmental assessments
- Other
- Lead sponsor
- Children's National Research Institute
- Other
- Eligibility
- 3 Years to 7 Years
- Enrollment
- 204 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Leishmaniasis
- Interventions
- Sodium Stibogluconate (SSG)
- Drug
- Lead sponsor
- U.S. Army Medical Research and Development Command
- Federal
- Eligibility
- Not listed
- Enrollment
- 414 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Malaria
- Interventions
- D/ChAd63-CA, D/ChAd63-CAT, Infectivity Control (IC) Group
- Biological · Other
- Lead sponsor
- U.S. Army Medical Research and Development Command
- Federal
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Silver Spring, Maryland
- Conditions
- Post-Lyme Disease Syndrome (PLDS)
- Interventions
- ReaLife+ (RLP), Inert Brown powder
- Dietary Supplement · Other
- Lead sponsor
- Optimal Health Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Dengue
- Interventions
- rDEN1Δ30, Placebo, rDEN2Δ30-7169
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Beta-Thalassemia
- Interventions
- LentiGlobin BB305 Drug Product
- Genetic
- Lead sponsor
- Genetix Biotherapeutics Inc.
- Industry
- Eligibility
- 0 Years to 50 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 3
- States / cities
- Oakland, California • Chicago, Illinois • Philadelphia, Pennsylvania
- Conditions
- Hemophilia B
- Interventions
- Gene Transfer, scAAV2/8-LP1-hFIXco
- Genetic · Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2026
- U.S. locations
- 3
- States / cities
- Stanford, California • Memphis, Tennessee • Temple, Texas
- Conditions
- Dengue
- Interventions
- D1ME100 (dengue-1 premembrane/envelope DNA vaccine)
- Biological
- Lead sponsor
- U.S. Army Medical Research and Development Command
- Federal
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Silver Spring, Maryland
- Conditions
- Dystrophic Epidermolysis Bullosa
- Interventions
- Topical beremagene geperpavec, Placebo gel
- Biological
- Lead sponsor
- Krystal Biotech, Inc.
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Plasmodium Falciparum Malaria
- Interventions
- AMA1-C1/Alhydrogel®, CPG 7909 Oligodeoxynucleotide (VaxImmune®)
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Small Cell Lung Cancer
- Interventions
- Paclitaxel, Drug: Ad.p53-DC vaccines, All -trans Retinoic Acid (ATRA)
- Drug · Biological
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2019
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- SARS-CoV-2 Infection
- Interventions
- B/HPIV3/S-6P
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Bladder Cancer, High Grade, Non Muscle Invasive
- Interventions
- oncolytic adenovirus expressing GMCSF
- Biological
- Lead sponsor
- CG Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona